Total costs and predictors of costs in patients with systemic lupus erythematosus

Rheumatology

Volumn 40, Issue 1, 2001, Pages 37-47

  Sutcliffe, N ^a,d   Clarke, A E ^b   Taylor, R ^c   Frost, C ^c   Isenberg, D A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MONTREAL GENERAL HOSPITAL   (Canada)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d Centre for Rheumatology   (United Kingdom)

Author keywords

Direct costs; Indirect costs; Predictors of costs; SLE; Total costs

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ACTIVITY; EDUCATION; EMPLOYMENT; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; OUTCOMES RESEARCH; PATIENT SATISFACTION; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; QUESTIONNAIRE; REGRESSION ANALYSIS; SOCIAL SUPPORT; SOCIETY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADOLESCENT; ADULT; AGED; COST OF ILLNESS; COSTS AND COST ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; QUESTIONNAIRES;

EID: 0035146359     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Health care economics and policy
2. The economic cost and social and psychological impact of musculoskeletal conditions
3. Clinical audit, the cost of rheumatoid arthritis
4. Direct cost of rheumatoid arthritis during the first six years: A cost of illness study
5. A Canadian study of the total medical costs for patients with systemic lupus erythematosus and the predictors of costs
6. Decreasing costs and improving outcomes in systemic lupus erythematosus: Using regression trees to develop health policy
7. An international perspective on the well-being and health care costs for patients with systemic lupus erythematosus
8. Associates of health status in patients with systemic lupus erythematosus
9. The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus
10. Underestimating the value of women: Assessing the indirect costs of women with systemic lupus erythematosus
11. The use of alternative medical therapies in patients with systemic lupus erythematosus
12. Why health care costs more in the US: Comparing health care expenditures between SLE patients in Stanford and Montreal
13. Health care research and policy studies
14. Cost-effectiveness in health and medicine
15. Costs of illness and the burden of disease
16. The 1982 revised criteria for the classification of systemic lupus erythematosus
17. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: Internal validation
18. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus
19. Cross cultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus
20. The development and initial validation of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage Index for Systemic Lupus Erythematosus
21. SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus
22. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus
23. The SF-36 health survey questionnaire: An outcome measure suitable for routine use within the NHS
24. Criterion validity and reliability of the SF-36 in a population sample
25. Consistency and validity of patient administered assessment of quality of life by the MOS SF-36: Its association with disease activity and damage in patients with systemic lupus erythematosus
26. Measuring the functional components of social support
27. Defining and measuring patient satisfaction with medical care
28. Measurement of patient outcome in arthritis
29. The direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: A twelve year study
30. Analysis and interpretation of cost data in randomised controlled trials: Review of published studies
31. Some comments on Cp
32. Hospital at home or acute hospital care? A cost minimisation analysis
33. Randomised controlled trial comparing hospital at home care with inpatient hospital care. II: Cost minimisation analysis
34. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
35. Home production. A survey
36. Wage determinants: A survey and reinterpretation of human capital earnings functions
37. Economic costs of systemic lupus erythematosus: A five year prospective study